
		Search


	Submit Manuscripts
	Author Information
	Subscribe/Renew
	Order Reprints
	Email Alerts
	Feedback
	RSS Feed
	CME


	About the Journal
	Editorial Board & Staff


	About JACC CME
	Hardware/Software Requirements
	Contact Us
	Policy on Privacy and Confidentiality
	Copyright Information


Still not a subscriber to JACC Imaging or JACC Interventions? Click here to sign up now!


	ACC.org
	Cardiosmart
	Cardiosource
	CVN
	Imaging Library
	JACC Imaging
	JACC Interventions

2009 Focused Updates: ACC/AHA Guidelines for STEMI and ACC/AHA/SCAI Guidelines for PCI

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery

ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research

	Help viewing high resolution images
	Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.

Figure 2 Plasma Lp-PLA₂ Activity

The results are presented as geometric means with 95% confidence interval. All doses of darapladib produced highly significant inhibition of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) activity when compared with placebo at weeks 4 and 12 (p < 0.001).

Return to article